Screening before and during the use of oral contraceptives and hormone replacement therapy

Human Reproduction

Volumn 15, Issue 2, 2000, Pages 485-492

  Crosignani, P G ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Hormone replacement therapy; Oral contraceptives; Screening

Indexed keywords

ESTROGEN; LIPID; LIPOPROTEIN;

ARTICLE; BLOOD PRESSURE MONITORING; COST EFFECTIVENESS ANALYSIS; EARLY DIAGNOSIS; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LIVER FUNCTION; ORAL CONTRACEPTION; PHYSICAL EXAMINATION; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PUBLIC HEALTH; SCREENING; THROMBOEMBOLISM;

EID: 0033972432     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Briet, E., van der Meer, F.J.M., Rodendaal, ER. et al. (1994) The family history and inherited thrombophilia. Br. J. Haematol., 87, 348-352.
2. Campos, H., Sacks, P.M., Walsh, B.W. et al. (1993) Differential effects of estrogen on low-density lipoprotein subclasses in healthy postmenopausal women. Metabolism, 42, 1153-1158.
3. Crook, D., Cust, M.P., Gangar, K.F. et al. (1992) Comparison of transdermal and oral estrogen/progestin hormone replacement therapy: effects on serum lipids and lipoproteins. Am. J. Obstet. GynecoL, 166, 950-955.
4. Crook, D., Godsland, I.F., Worthington, M. et al. (1993) A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins. Am. J. Obstet. Gynecol., 169, 1183-1189.
5. Crook, D., Godsland, I.F., Hull, J. and Stevenson, J.C. (1997) Hormone replacement therapy with dydrogesterone and oestradiol-17ß: effects on serum lipoproteins and glucose tolerance. Br. J. Obstet. Gynaecol., 104, 298-304.
6. Delmas, P.D. and Garnero, P. (1998) Biological markers of bone turnover in osteoporosis. In Stevenson, J.C. and Lindsay, R. (eds), Osleoporosis. Chapman and Hall, London, pp. 117-136.
7. de Ronde, H. and Bertina, R.M. (1994) Laboratory diagnosis of APC-resistance. A critical evaluation of the test and the development of diagnostic criteria. Thrombos. Haemost., 72, 880-886.
8. Parley, T.M.M., Collins, J. and Schlesselman, J.J. (1998) Hormonal contraception and risk of cardiovascular disease: an international perspective. Contraception, 57, 211-230.
9. Farmer, R.D.T. and Preston, T.D. (1995) The risk of venous thromboembolism associated with low oestrogen oral contraceptives. J. Obstet. Gynaecol., 15, 195-200.
10. Garnero, P., Hausherr, E., Chapuy, M.C. et al. (1996) Markers of bone résorption predict hip fracture in elderly women. J. Bone Mm. Res., 11, 1531-1538.
11. Gerstman, B.B., Piper, J.M., Tomita, O.K. et al. (199I) Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am. J. Epidemiol., 133, 32-37.
12. Godsland, I.F., Crook, D., Simpson, R. et al. (1990) The effects of different formulations or oral contraceptive agents on lipid and carbohydrate metabolism. N. EngJ. J. Med., 232, 1375-1381.
13. Hannaford, P.C. and Webb, A.M.C. on behalf of participants of an international workshop (1996a) Evidence-guided prescribing of combined oral contraceptives: consensus statement. Contraception, 54, 125-129.
14. Hannaford P.C. and Webb, A.M.C. (eds) (1996b) Evidence-winded Prescribing of the Pill. Parthenon, Carnforth, UK.
15. Hannaford, P.C., Kay, C.R., Vessey, M.P. et al. (1997) Combined oral contraceptives and liver disease. Contraception, 55, 145-151.
16. Heinemann, L.A.J., Lewis, M.A., Thorogood, M. et al. (1997) Oral contraceptives and risk of thromboembolic stroke: results from international study on oral contraceptives and health of young women. Br. Med. J., 315, 1502-1504.
17. Hulley, S., Grady, D., Bush, T. et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J. Am. Med. Assoc., 280, 605-613.
18. Koster, T., Rosendaal, F.R., de Ronde, H. et al. (1993) Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet, 342, 1503-1506.
19. Krauss, R.M. (1991) The tangled web of coronary risk factors. Am. J. Med., 90 (Suppl. 2A), 36-41.
20. Lees, B., Banks, L.M. and Stevenson, J.C. (1998) Bone mass measurements. In Stevenson, J.C. and Lindsay, R. (eds), Osteoporosis. Chapman and Hall, London, pp. 137-160.
21. Lewis, M.A., Heinemann, L.A.J., Spitzer, W.O. et al. for the Transnational Research Group on Oral Contraceptives and the Health of Young Women (1997) The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception, 56, 129-140.
22. MacMahon, S., Peto, R., Cutler, J. et al. (1990) Blood pressure, stroke and coronary heart disease: Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet, 335, 765-774.
23. Mant, D. and Fowler, G. (1990) Mass screenina: theory and ethics. Br. Med. J., 300, 916-918.
24. Miller, N.E. (1987) Associations of high-density lipoprotein subclasses and apolipoproteins with ischaemic heart disease and coronary atherosclerosis. Am. Heart J., 113, 589-597.
25. Osterud, B., Robertsen, A., Asvang, G.B. and Thyssen, F. (1994) Resistance to activated protein C is reduced in women using oral contraceptives. Blood Coag. Fibrin., 5, 853-854.
26. Petitti, D.B., Sidney, S., Bernstein, A. et al. (1996) Stroke in users of low-dose oral contraceptives. N. Engl. J. Med., 335, 8-15.
27. Schwanz, S.M., Siscovick, D.S., Longstreth, W.T., et al. (1997) Use of low-dose oral contraceptives and health of young women. Ann. Intern. Med., 127, 596-603.
28. Shelton, J.D., Angle, M.A. and Jacobstein, R.A. (1982) Medical barriers to access to family planning. Lancet, 340, 1334-1335.
29. Sidney, S., Petitti, D.B., Quesenberry, C.P. et al. (1996) Myocardial infarction in users of low-dose oral contraceptives. Obstet. Gynecol., 88, 939-944.
30. Speroff, L., DeCherney, A. and the Advisory Board for the New Progestins (1993) Evaluation of a new generation of oral contraceptives. Obstet. Gynecol., 81, 1034-1047.
31. Stevenson, J.C. (1996) Metabolic effects of the menopause and oestrogenreplacement. In Barlow, D.H. (ed.), Balliere's Clinical Obstetrics and Gynaecology. Tlie Menopause: Key Issues. Baillière Tindall, London. pp. 449-167.
32. Stevenson, J.C. (1997a) Hormone replacement therapy and lipids. Menopause Rev., 2, 15-20.
33. Stevenson, J.C. (1997b) Gonadal hormones. Osteoporosis Int., 7 (Suppl. 1), 58-60.
34. Stewart-Brown, S. and Farmer, A. (1997) Screening could seriously damage your health. Dr. Med. J., 314, 533-534.
35. United Nations (1996) World Economic and Social Survey 1996: Trends and Policies in the World Economy. United Nations, New York.
36. Vandenbroucke, J.P., Koster, T., Briet, E. et al. (1994) Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor Leiden mutation. Lancet, 344, 1453-1457.
37. van der Meer, F.J.M., Koster, T., Vandenbroucke, J.P. et al. (1997) The Leiden Thrombophilia Study (LETS). Thrombos. Haemostas., 78, 631-635.
38. van der Vange, N., Kloosterboer, HJ. and Haspels, A.A. (1987) Effect of seven low-dose combined oral contraceptive preparations on carbohydrate metabolism. Am. J. Obstet. Gynecol, 156, 918-922.
39. Westerveld, H.T., Kock, L.A.W., van Rijn, J.M. et al. (1995) 17ß-estradiol improves postprandial lipid metabolism in postmenopausal women. J. din. Endocrinol. Metab., 80, 249-253.
40. Wilson, J.M.G. and Dungree, G. (1968) Principles and Practice of Screening for Disease. World Health Organization, Geneva.
41. Winkler, U.H. (1996) Role of screening for vascular disease in pill users: the hemostatic system. In Hannaford, P.C, and Webb, A.M.C. (eds), Evidence-guided Prescribing of the Pill. Parthenon, London, pp. 109-120.
42. World Health Organization (1993) World Health Statistics Annual 1992. World Health Organization, Geneva.
43. World Health Organization (1994) World Health Statistics Annual 1993. World Health Organization, Geneva.
44. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995a) A multinational case-control study of a cardiovascular disease and steroid hormone contraceptives. Description and validation of methods. J. Clin. EpidemioL, 48, 1513-1547.
45. World Health Organization (1995b) World Health Statistics Annual 1994. World Health Organization, Geneva.
46. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1996) Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet, 348, 505-510.
47. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1996a) Ischaemic stroke and combined oral contraceptives: results of an international multicentre, case-control study. Lancet, 348, 498-505.
48. World Health Organization (1996b) World Health Statistics Annual 1995. World Health Organization, Geneva.
49. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1997) Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet, 349, 1202-1209.
50. World Health Organization Scientific Group on Cardiovascular Disease and Steroid Hormone Contraception ( 1998a) Cardiovascular Disease and Steroid Hormone Contraception: Report of a WHO Scientific Group. WHO Technical Report Series. World Health Organization, Geneva, p. 89.
51. World Health Organization (1998b) World Health Statistics Annual 1996. World Health Organization, Geneva.